Nucleic Acid News and Research

RSS

Improving tuberculosis (TB) diagnosis: an interview with Professor Madhukar Pai, MD, PhD

TB is an infectious disease caused by Mycobacterium tuberculosis. Nearly 9 million people develop TB every year, and TB kills nearly 1.4 million individuals each year. While the incidence of TB has steadily declined in the west, it remains a huge public health problem in many developing countries, with India having the highest burden.

15 Feb 2013

Nucleic Acid Therapeutics publishes special research section on noncoding RNAs

As scientists continue to unravel the complexity of the human genome and to uncover vital elements that play a role in both normal physiology and disease, one particular class of elements called noncoding RNAs is gaining a lot of attention. Guest Editor Tom Cech, PhD and Executive Editor Fintan Steele, PhD explore the enormous potential value of this rapidly advancing research area in their Editorial " The (Noncoding) RNA World."

15 Feb 2013

DNAzymes and gold nanoparticles used to detect infectious diseases

Infectious diseases such as malaria and syphilis can be diagnosed rapidly and reliably in the field by using a simple test developed by Canadian scientists. The test is based on the use of DNAzymes and gold nanoparticles. As the researchers report in the journal Angewandte Chemie, their test allows for the sensitive detection of bacteria, viruses, and parasites.

12 Feb 2013

Non-coding RNA MALAT1 influences lung cancer metastasis

The vast majority - approximately 80 percent - of our DNA does not code for proteins, yet it gets transcribed into RNA. These RNA molecules are called non-coding and fulfill multiple tasks in the cell. Alongside a well-studied group of small RNAs, there is also a class of so-called long non-coding RNAs consisting of more than 200 nucleotides.

6 Feb 2013

Flow cytometry can now be used for quantification of microbial cells in drinking water

Flow cytometry (FCM) can now be officially used for the quantification of microbial cells in drinking water. The new analytical method - developed at Eawag and extensively tested both in Switzerland and abroad - has been incorporated into the Swiss Food Compendium (SLMB) by the Federal Office of Public Health (FOPH).

25 Jan 2013

New apatamer can boost therapeutic effect of cell-based vaccines

A small compound called an aptamer that specifically targets and stimulates a human immune cell can greatly increase the effectiveness of an immunotherapeutic drug designed to destroy malignant or virus-infected cells. The development of a novel apatamer that recognizes activated T-lymphocytes and can boost the therapeutic effect of cell-based vaccines is described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.

23 Jan 2013

FDA categorizes Cepheid's Xpert CT/NG test as 'Moderate Complexity' under CLIA

Cepheid today announced the U.S. Food & Drug Administration (FDA) has categorized Cepheid's Xpert CT/NG test as 'Moderate Complexity' under the Clinical Laboratory Improvement Amendments (CLIA).

17 Jan 2013

New method based on mass sequencing can detect hereditary breast and ovarian cancer syndrome

Researchers of the Catalan Institute of Oncology (ICO) at the Bellvitge Biomedical Research Institute (IDIBELL) have developed and validated a new method to diagnose hereditary breast and ovarian cancer syndrome based on mass sequencing of BRCA1 and BRCA2 genes. The model is based on a genetic and bioinformatic analysis which has been proved very effective.

17 Jan 2013

FDA clears Hologic's APTIMA Trichomonas vaginalis Assay

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that the U.S. Food and Drug Administration (FDA) has cleared for marketing its APTIMA Trichomonas vaginalis Assay on the Company's fully-automated PANTHER System.

From Hologic, Inc. 15 Jan 2013

Roche, PSS partner to develop fully automated emulsion PCR instrument for sequencing

Roche and Precision System Science, Co., Ltd (PSS) today announced the signing of an exclusive agreement to develop and manufacture a fully automated emulsion PCR instrument for Roche's portfolio of next-generation sequencing platforms. It is intended to support Roche's GS Junior and GS FLX+ systems as well as the sequencing platforms that Roche is currently developing.

From Roche Sequencing and Life Science 21 Dec 2012

CNIO creates 2 new databases to study the human genome

Scientists from the Structural Computational Biology Group at the Spanish National Cancer Research Centre (CNIO), led by Alfonso Valencia, together with French and American researchers, have published recently two articles in the journal Nucleic Acid Research (NAR) that introduce two new databases for studying the human genome.

18 Dec 2012

Meridian completes beta trials for two new illumigene molecular amplification tests

Meridian Bioscience, Inc. today announced that it has successfully completed beta trials for two new illumigene molecular amplification tests.

14 Dec 2012

3M Molecular detection assay Salmonella certified by AFNOR Certification

3M Food Safety today announced its 3M™ Molecular Detection Assay Salmonella received an NF VALIDATION mark from AFNOR Certification. The Salmonella assay was among three pathogen test kits the company introduced alongside its novel 3M™ Molecular Detection System less than a year ago. In April, AOAC Research Institute granted PTM SM certification of the Salmonella assay, another important confirmation of the technology's effectiveness in detecting the bacteria.

13 Dec 2012

Bio-Path to initiate BP-100-1.01 Phase I trial for treatment of two types of breast cancer

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced it is initiating development of its lead cancer drug BP-100-1.01 (Liposomal Grb-2) to treat triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates.

6 Dec 2012

Inovio's SynCon DNA vaccine effective at inducing CD8+ T cell responses specific to CMV

Inovio Pharmaceuticals, Inc. announced today that testing of multiple synthetic vaccine constructs for cytomegalovirus (CMV) induced robust T cells in mice, demonstrating the potential for a SynCon DNA vaccine to treat this virus that causes infant death and congenital abnormalities, is associated with cerebral palsy and brain tumors, and is the most common viral infection in organ transplant recipients. CMV is also associated with numerous inflammatory diseases and cancers, and is implicated in hypertension, a major risk factor for cardiovascular diseases.

26 Nov 2012

Scientists develop new prototype ultra sensitive disease sensor

Scientists have developed a prototype ultra-sensitive sensor that would enable doctors to detect the early stages of diseases and viruses with the naked eye, according to research published today in the journal Nature Nanotechnology.

29 Oct 2012

Global anti-tuberculosis campaign now ‘at a crossroads’

Tuberculosis care and control has improved dramatically over the last two decades, but numbers of cases and deaths are still high and multidrug resistant-TB is an under-reported and ever-increasing problem, suggest findings from the World Health Organization Global TB Report 2012.

18 Oct 2012

Thermo Fisher Scientific introduces MYECL Imager instrument

Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Thermo Scientific MYECL Imager, an easy-to-use imaging instrument that delivers one-touch image capture and analysis of protein and nucleic acid gels and Western blots.

From Thermo Fisher Scientific Inc. 17 Oct 2012

Roche announces availability of new HIV-1 viral load test in the U.S.

Roche announced today the U.S. availability of a new HIV-1 viral load test based on the company's proprietary dual-target approach. The COBAS TaqMan HIV-1 Test v2.0 for use with the High Pure System enables labs to combine an FDA-approved process for manual specimen preparation with an automated real-time PCR analyzer for amplification and detection.

From Roche Sequencing and Life Science 4 Oct 2012

Thermo Fisher Scientific announces opening of Molecular Biology Center of Excellence in Lithuania

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the official opening of its Molecular Biology Center of Excellence in Vilnius, Lithuania.

From Thermo Fisher Scientific Inc. 20 Sep 2012